We are Scientists at heart. That means that we work every day to provide solutions in key therapeutic areas, bringing new treatments to market in the field of dermatology, as well as having a significant interest in pain relief medications.
Our R&D in key therapeutic areas.
Here are some of the key breakthrough medicines resulting from our Proprietary R&D:
We invested 12.9% of our net sales in R&D in 2016.
More than 270 of our professionals are dedicated to R&D.
We have 3 R&D Centres in Europe.
Almirall has over 270 qualified professionals working in R&D in 3 centres in Spain, Switzerland & Germany. We also count on the contributions of a group in the USA dedicated to clinical and regulatory activities.
Almirall R&D site in Lugano (Switzerland): Polichem.
The company, with R&D site base in Lugano, was adquired in 2016.
Polichem's core business focuses on dermatology and dermocosmetics, gynaecology and respiratory disorders. It owns a broad portfolio of patents granted in many countries all over the world, including the USA, covering original formulations and pharmaceutical technologies applicable across a wide range of therapeutic areas. Following a ‘forward-looking vision', Polichem owns innovative patent-protected development projects in various medical fields with a particular focus on specific skin conditions.